This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
  • 00
  • 00
  • 00
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

JCR Pharmaceuticals Co., Ltd.


JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values - reliability, confidence, and persistence - benefit all our stakeholders, including employees, partners, and patients. JCR succeeded in commercializing the world's first "technology delivering active ingredients to the brain," our proprietary blood-brain barrier (BBB) penetration technology, J-Brain Cargo®. IZCARGO®, a recombinant treatment for mucopolysaccharidosis II (MPS II), was launched in Japan in May 2021. JCR concluded a joint development and commercialization agreement with Takeda in September 2021 to deliver the groundbreaking new drug to people around the world as soon as possible. In February 2022, dosing started on the first patients in Phase III global clinical trials for JR-141 in the U.S., Brazil, and Europe.